Literature DB >> 16622211

Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine.

Casie Kelly-Quintos1, Lisa A Cavacini, Marshall R Posner, Donald Goldmann, Gerald B Pier.   

Abstract

Carbohydrate antigens are important targets of the immune system in clearing bacterial pathogens. Although the immune system almost exclusively uses antibodies in response to foreign carbohydrates, there is still much to learn about the role of different epitopes on the carbohydrate as targets of protective immunity. We examined the role of acetyl group-dependent and -independent epitopes on the staphylococcal surface of polysaccharide poly-N-acetylated glucosamine (PNAG) by use of human monoclonal antibodies (MAbs) specific for such epitopes. We utilized hybridoma technology to produce fully human immunoglobulin G2 (IgG2) MAbs from B cells of an individual post-Staphylococcus aureus infection and cloned the antibody variable regions to produce an IgG1 form of each original MAb. Specificity and functionality of the purified MAbs were tested in vitro using enzyme-linked immunosorbent assays, complement deposition, and opsonophagocytic assays. We found that a MAb (MAb F598) that bound the best to nonacetylated or backbone epitopes on PNAG had superior complement deposition and opsonophagocytic activity compared to two MAbs that bound optimally to PNAG that was expressed with a native level (>90%) of N-acetyl groups (MAbs F628 and F630). Protection of mice against lethality due to S. aureus strains Mn8 and Reynolds further showed that the backbone-specific MAb had optimal protective efficacy compared with the acetate-specific MAbs. These results provide evidence for the importance of epitope specificity in inducing the optimal protective antibody response to PNAG and indicate that MAbs to the deacetylated form of PNAG could be immunotherapeutic agents for preventing or treating staphylococcal infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622211      PMCID: PMC1459728          DOI: 10.1128/IAI.74.5.2742-2750.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

1.  Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F.

Authors:  Jianhui Zhou; Kathleen R Lottenbach; Stephen J Barenkamp; Alexander H Lucas; Donald C Reason
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 2.  Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance.

Authors:  Sylvain DeLisle; Trish M Perl
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

Review 3.  Protective antibodies and endemic dimorphic fungi.

Authors:  J D Nosanchuk
Journal:  Curr Mol Med       Date:  2005-06       Impact factor: 2.222

4.  Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a collagen substrate.

Authors:  L Visai; Y Xu; F Casolini; S Rindi; M Höök; P Speziale
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

5.  Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.

Authors:  Paul J Domanski; Pratiksha R Patel; Arnold S Bayer; Li Zhang; Andrea E Hall; Peter J Syribeys; Elena L Gorovits; Dawn Bryant; John H Vernachio; Jeff T Hutchins; Joseph M Patti
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 6.  Antibodies: can they protect against HIV infection?

Authors:  C M Mc Cann; R J Song; R M Ruprecht
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

7.  Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat.

Authors:  A Rennermalm; Y H Li; L Bohaufs; C Jarstrand; A Brauner; F R Brennan; J I Flock
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641

Review 8.  Anticancer antibodies.

Authors:  Jeffrey S Ross; Karen Gray; Gary S Gray; Peter J Worland; Mark Rolfe
Journal:  Am J Clin Pathol       Date:  2003-04       Impact factor: 2.493

9.  Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide.

Authors:  Tomás Maira-Litrán; Andrea Kropec; C Abeygunawardana; Joseph Joyce; George Mark; Donald A Goldmann; Gerald B Pier
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 10.  Infliximab treatment of rheumatoid arthritis and Crohn's disease.

Authors:  Ibrahim K Nahar; Kam Shojania; Carlo A Marra; Abul H Alamgir; Aslam H Anis
Journal:  Ann Pharmacother       Date:  2003-09       Impact factor: 3.154

View more
  53 in total

1.  Role of a putative polysaccharide locus in Bordetella biofilm development.

Authors:  Gina Parise; Meenu Mishra; Yoshikane Itoh; Tony Romeo; Rajendar Deora
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

Review 2.  The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG.

Authors:  David Skurnik; Colette Cywes-Bentley; Gerald B Pier
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

Review 3.  Staphylococcal biofilms.

Authors:  M Otto
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

4.  Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection.

Authors:  David Skurnik; Michael R Davis; Dennis Benedetti; Katie L Moravec; Colette Cywes-Bentley; Damien Roux; David C Traficante; Rebecca L Walsh; Tomas Maira-Litràn; Sara K Cassidy; Christina R Hermos; Thomas R Martin; Erin L Thakkallapalli; Sara O Vargas; Alexander J McAdam; Tami D Lieberman; Roy Kishony; John J Lipuma; Gerald B Pier; Joanna B Goldberg; Gregory P Priebe
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

5.  Label-free electrical sensing of bacteria in eye wash samples: A step towards point-of-care detection of pathogens in patients with infectious keratitis.

Authors:  Hardik J Pandya; Manoj Kumar Kanakasabapathy; Saloni Verma; Manjyot Kaur Chug; Adnan Memic; Mihaela Gadjeva; Hadi Shafiee
Journal:  Biosens Bioelectron       Date:  2016-12-13       Impact factor: 10.618

6.  Molecular basis for preferential protective efficacy of antibodies directed to the poorly acetylated form of staphylococcal poly-N-acetyl-beta-(1-6)-glucosamine.

Authors:  Nuno Cerca; Kimberly K Jefferson; Tomas Maira-Litrán; Danielle B Pier; Casie Kelly-Quintos; Donald A Goldmann; Joana Azeredo; Gerald B Pier
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

7.  Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens.

Authors:  Colette Cywes-Bentley; David Skurnik; Tanweer Zaidi; Damien Roux; Rosane B Deoliveira; Wendy S Garrett; Xi Lu; Jennifer O'Malley; Kathryn Kinzel; Tauqeer Zaidi; Astrid Rey; Christophe Perrin; Raina N Fichorova; Alexander K K Kayatani; Tomas Maira-Litràn; Marina L Gening; Yury E Tsvetkov; Nikolay E Nifantiev; Lauren O Bakaletz; Stephen I Pelton; Douglas T Golenbock; Gerald B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-28       Impact factor: 11.205

8.  Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens.

Authors:  Marina L Gening; Tomás Maira-Litrán; Andrea Kropec; David Skurnik; Martha Grout; Yury E Tsvetkov; Nikolay E Nifantiev; Gerald B Pier
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

9.  Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae.

Authors:  David Skurnik; Damien Roux; Stephanie Pons; Thomas Guillard; Xi Lu; Colette Cywes-Bentley; Gerald B Pier
Journal:  J Antimicrob Chemother       Date:  2016-01-07       Impact factor: 5.790

Review 10.  Invariant natural killer T cells: front line fighters in the war against pathogenic microbes.

Authors:  Catherine M Crosby; Mitchell Kronenberg
Journal:  Immunogenetics       Date:  2016-07-01       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.